68Ga-DOTA-NT-20.3

N/A

Report date: 2025/11/20 16:02:18

NME

Base Information

Drug Name68Ga-DOTA-NT-20.3

Drug Alias NameN/A

ClassificationRadiation-emitting products > Nuclides > Gallium > 68GaRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Radionuclide Drug Conjugates +[4]

Mechanisms of ActionNeurotensin receptor 1 binders

TargetsNeurotensin receptor 1

Therapy Area/IndicationsCarcinoma, Pancreatic Ductal

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusClinical

Highest Status in ChinaClinical

Originator CompaniesNanjing First Hospital, Nanjing Medical University

China Registration ClassN/A

Develop Information

Active CompaniesNanjing First Hospital, Nanjing Medical University

Inactive CompaniesN/A

Active IndicationsCarcinoma, Pancreatic Ductal

Inactive IndicationsN/A

Other Information

ATC CodeN/A